Ionis Pharmaceuticals Inc (IONS)
41.97
-1.12
(-2.60%)
USD |
NASDAQ |
May 03, 16:00
41.97
0.00 (0.00%)
Pre-Market: 20:00
Ionis Pharmaceuticals Enterprise Value: 5.073B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 5.073B |
| May 02, 2024 | 5.236B |
| May 01, 2024 | 5.224B |
| April 30, 2024 | 4.969B |
| April 29, 2024 | 5.076B |
| April 26, 2024 | 5.017B |
| April 25, 2024 | 5.054B |
| April 24, 2024 | 5.143B |
| April 23, 2024 | 5.054B |
| April 22, 2024 | 4.941B |
| April 19, 2024 | 4.884B |
| April 18, 2024 | 4.903B |
| April 17, 2024 | 4.918B |
| April 16, 2024 | 5.010B |
| April 15, 2024 | 5.011B |
| April 12, 2024 | 5.039B |
| April 11, 2024 | 5.150B |
| April 10, 2024 | 5.214B |
| April 09, 2024 | 5.198B |
| April 08, 2024 | 5.112B |
| April 05, 2024 | 5.255B |
| April 04, 2024 | 5.198B |
| April 03, 2024 | 5.337B |
| April 02, 2024 | 5.223B |
| April 01, 2024 | 5.360B |
| Date | Value |
|---|---|
| March 28, 2024 | 5.270B |
| March 27, 2024 | 5.461B |
| March 26, 2024 | 5.381B |
| March 25, 2024 | 5.351B |
| March 22, 2024 | 5.178B |
| March 21, 2024 | 5.182B |
| March 20, 2024 | 5.187B |
| March 19, 2024 | 5.096B |
| March 18, 2024 | 5.077B |
| March 15, 2024 | 5.153B |
| March 14, 2024 | 5.099B |
| March 13, 2024 | 5.242B |
| March 12, 2024 | 5.244B |
| March 11, 2024 | 5.257B |
| March 08, 2024 | 5.363B |
| March 07, 2024 | 5.462B |
| March 06, 2024 | 5.407B |
| March 05, 2024 | 5.392B |
| March 04, 2024 | 5.491B |
| March 01, 2024 | 5.577B |
| February 29, 2024 | 5.541B |
| February 28, 2024 | 5.735B |
| February 27, 2024 | 5.862B |
| February 26, 2024 | 5.671B |
| February 23, 2024 | 5.563B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.911B
Minimum
Dec 01 2021
8.770B
Maximum
May 06 2019
5.508B
Average
5.306B
Median
Oct 04 2023
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 4.055B |
| Viking Therapeutics Inc | 7.524B |
| Alnylam Pharmaceuticals Inc | 17.92B |
| Akero Therapeutics Inc | 830.46M |
| 89bio Inc | 323.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.263M |
| Revenue (Quarterly) | 324.50M |
| Total Expenses (Quarterly) | 330.62M |
| EPS Diluted (Quarterly) | -0.06 |
| Gross Profit Margin (Quarterly) | 99.06% |
| Profit Margin (Quarterly) | -2.85% |
| Earnings Yield | -6.10% |
| Normalized Earnings Yield | -7.242 |